Sequoia Financial Advisors LLC Purchases 2,222 Shares of DexCom, Inc. (NASDAQ:DXCM)

Sequoia Financial Advisors LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 35.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,489 shares of the medical device company’s stock after acquiring an additional 2,222 shares during the period. Sequoia Financial Advisors LLC’s holdings in DexCom were worth $660,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Versant Capital Management Inc purchased a new position in DexCom in the fourth quarter worth $25,000. Private Trust Co. NA raised its stake in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the period. Larson Financial Group LLC boosted its holdings in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after buying an additional 137 shares during the last quarter. Heck Capital Advisors LLC bought a new position in DexCom during the fourth quarter valued at about $38,000. Finally, SBI Securities Co. Ltd. purchased a new stake in DexCom during the fourth quarter worth about $49,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Trading Up 0.9 %

Shares of DexCom stock opened at $71.35 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The firm has a market cap of $27.88 billion, a PE ratio of 49.90, a PEG ratio of 2.30 and a beta of 1.28. The company has a 50 day simple moving average of $83.82 and a two-hundred day simple moving average of $76.94.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on DXCM shares. Canaccord Genuity Group increased their target price on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Citigroup boosted their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $99.82.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the sale, the chief operating officer now directly owns 313,497 shares of the company’s stock, valued at $22,063,918.86. The trade was a 4.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 104,657 shares of company stock valued at $8,019,422. Corporate insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.